

Company Fact Sheet

CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies to treat people in more than 100 countries with serious and life-threatening medical conditions.

We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.

Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop and dependably deliver innovations that patients and providers want.

We have more than 1,700 dedicated scientists who focus on solving patients' unmet needs. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (AXS:CSL; USOTC:CSLLY), is headquartered in Melbourne, Australia.

INNOVATION

CSL Behring's commitment to innovation is reflected in breakthrough therapies currently in development to reduce the risk of early recurrent cardiovascular events, improve outcomes in organ transplant, and treat sickle cell disease, β -thalassemia and autoimmune diseases.

THERAPEUTIC AREAS

- Immunology
- Hematology
- Respiratory
- Cardiovascular and Metabolic
- Transplant

EMPLOYEES

27,000+ employees worldwide

OPERATIONAL HEADQUARTERS

King of Prussia, Pennsylvania, USA

PLASMA COLLECTION

More than 275 collection centers in the USA and Europe


MANUFACTURING

Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; Kankakee, Illinois, USA; Wuhan, China

2019-2020 | CSL Behring Sales – \$7.7 Billion

Therapeutic Group

Therapy	Sales \$m	% Change
Immunoglobulins	4,014	22%
Hemophilia	1,112	8%
Albumin*	640	(36%)
Specialty	1,572	10%
Other	188	(1%)
Total	7,661	8%



*Albumin sales grew strongly in key markets with the planned exception of China, where we transitioned to our new direct distribution model. The resulting decrease was in line with guidance.

For more information, visit

[CSLBehring.com](https://www.CSLBehring.com).

For inspiring stories about the promise of biotechnology, visit Vita at [CSLBehring.com/Vita](https://www.CSLBehring.com/Vita).

FOLLOW US ON

- [Twitter.com/CSLBehring \(@CSLBehring\)](https://twitter.com/CSLBehring)
- [linkedin.com/company/csl-behring](https://www.linkedin.com/company/csl-behring)